GlaxoSmithKline Pharmaceuticals Q4 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,667.45
47.65 (1.82%)
47.65 (1.82%)Volume3.55 K
Updated: Wed 11 Feb, 2026 | 12:59:04
NSE
2,672.3049.40 (1.88%)
49.40 (1.88%)Volume53.93 K
Updated: Wed 11 Feb, 2026 | 12:43:38
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 655.90 | 690.24 | -3.02% | 690.63 | -5.03% |
| Depreciation/ Amortization | 14.72 | 20.32 | -21.69% | 18.10 | -18.66% |
| Operating Income | 318.47 | 351.02 | 16.60% | 239.17 | 33.16% |
| Net Income | 262.87 | 295.62 | 14.35% | 194.48 | 35.17% |
| Other Operating Expenses Total | 136.27 | 154.22 | -21.50% | 132.58 | 2.78% |
| Net Income Before Taxes | 358.57 | 399.93 | 16.38% | 270.62 | 32.50% |
| Total Revenue | 974.37 | 1,041.26 | 2.63% | 929.80 | 4.79% |
| Selling/ General/ Admin Expenses Total | 152.97 | 151.88 | 22.63% | 172.83 | -11.49% |
| Diluted Normalized EPS | 15.51 | 16.67 | 14.33% | 11.37 | 36.43% |